{"filings":[{"id":108967,"accession_number":"0001493152-26-006428","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.","Net loss of $2.0M ($0.05/shr) vs $2.5M ($0.09/shr) in same quarter prior year.","Operating expenses flat at $2.6M; cash $9.0M plus $3.0M loan facility available.","Lead candidate selonabant: IV formulation Phase 1 SAD study started Sep 2025; prioritizing pediatric pathway.","Company cites cost savings from ending public reporting obligations as rationale for delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108966,"accession_number":"0001493152-26-005463","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Anebulo Pharmaceuticals voluntarily delisting from Nasdaq, terminating SEC registration effective Feb 27, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.","Form 25 to be filed on or about Feb 17; delisting expected effective Feb 27, 2026.","Form 15 to be filed on or about Feb 27 certifying fewer than 300 record holders, suspending SEC reporting.","Company is in compliance with Nasdaq rules; delisting decision based on cost of public company burdens outweighing benefits.","Following delisting, trading will occur only in privately negotiated sales or on the OTC market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108965,"accession_number":"0001493152-26-004154","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo completes oversubscribed tender offer, buys 300K shares at $3.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final count: 4,907,881 shares tendered, oversubscribed.","Accepted 300,000 shares (incl. 134,306 odd lots) at $3.50/share for ~$1.05M.","Proration factor 3.47392%; accepted shares = 0.73% of shares outstanding.","CEO: pleased to provide smaller stockholders opportunity to sell at premium to market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108964,"accession_number":"0001493152-26-003718","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo tender offer oversubscribed; 4.9M shares tendered, 300k accepted at $3.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,897,188 shares properly tendered (excluding 10,868 by guaranteed delivery).","Company expects to accept 300,000 shares at $3.50 each for total cost of ~$1.05M.","Proration factor approximately 3.51542%; odd lots accepted in full.","Shares accepted represent about 0.73% of outstanding as of Jan 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125416,"accession_number":"0001493152-25-028676","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo abandons reverse split, launches self-tender for up to 300k shares at $3.50/sh to go private","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abandons reverse stock split (1-for-2,500 to 1-for-7,500) due to cost increase from holders splitting shares to get multiple fractional payments.","Launches self-tender offer to purchase up to 300,000 shares at $3.50 per share, aggregate up to $1.05 million.","Tender offer designed to reduce stockholder count below 300, necessary for 'go private' transaction.","Board may revisit reverse split or alternative transaction in future if economically beneficial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125415,"accession_number":"0001493152-25-022310","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.","Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.","Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.","Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142152,"accession_number":"0001493152-25-016001","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.","Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.","Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.","Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142151,"accession_number":"0001493152-25-013133","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo updates on going private: Board to consider sale, merger, or other alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received inbound interest from potential financial and strategic partners after announcing going private on July 23, 2025.","Board will review all strategic alternatives including going private, reverse stock split, asset sale, or merger.","Company plans to hold special stockholder meeting to approve proposed reverse stock split while review continues.","No assurance that process will result in a transaction; no deadline or definitive timetable set.","Even if stockholders approve reverse stock split, Board could abandon it for any reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142150,"accession_number":"0001493152-25-011342","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo plans going-private via reverse split; $3.50/share for fractional shares, 91% premium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio range 1-for-2,500 to 1-for-7,500; stockholder vote at special meeting Aug 22, 2025.","Cash payment of $3.50 per pre-split share for fractional shares, representing a 91% premium to July 22 close.","Holders below 2,500-7,500 pre-split shares will be cashed out; holders above retain one post-split share per minimum.","Transaction aims to reduce record holders below 300 to terminate SEC registration; board may abandon at any time.","Company cites high cost of being public as burdensome; will focus on advancing selonabant IV formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160141,"accession_number":"0001641172-25-009952","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.","Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.","Cash $13.3M plus $3M loan facility; sufficient for planned operations.","Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.","FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160140,"accession_number":"0001641172-25-004799","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anebulo regains Nasdaq compliance on private placement share restrictions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5635(b) on April 11, 2025.","Removal of voting and transfer restrictions on shares issued in December 2024 private placement was approved by stockholders.","Matter is now closed; no further delisting risk from this issue.","Company disclosed the resolution in an 8-K filed April 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160139,"accession_number":"0001641172-25-003913","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Anebulo shareholders approve authorized share increase to 75M and board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved raising authorized common shares from 50M to 75M at the April 4, 2025 Annual Meeting.","Certificates of amendment filed with Delaware on April 11, 2025.","Stockholders also approved declassification of the Board; all directors will stand for annual election starting next meeting.","Board adopted conforming Bylaws amendment effective upon the declassification charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160138,"accession_number":"0001641172-25-002862","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anebulo shareholders approve authorized share increase to 75M, stock plan expansion, and removal of 10.1M-share lock-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 50M to 75M shares; stock incentive plan pool raised by 2.5M to 6.15M shares.","Voting and transfer restrictions on 10,101,010 shares held by 22NW Fund, LP removed per shareholder approval.","Class I directors Joseph F. Lawler, Richard Anthony Cunningham, Aron R. English re-elected.","Ratification of EisnerAmper LLP as independent auditor for fiscal 2025 approved.","All proposals passed with strong majorities; record date had 41,084,731 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178453,"accession_number":"0001493152-25-008080","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.","Company entered lock-up agreement with 22NW (Aron English) on Feb 24, 2025, restricting voting/sale of 10.1M shares until stockholder approval.","Nasdaq granted extension until April 10, 2025 to obtain stockholder approval; annual meeting scheduled April 4, 2025.","Joseph Lawler entities have agreed to vote in favor of removing lock-up restrictions, which would ratify the change of control.","Failure to obtain stockholder approval by April 10, 2025 may result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178452,"accession_number":"0001493152-25-006875","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.","Cash and equivalents $15.0M as of Dec 31, 2024; additional $3M available under amended loan.","FDA acknowledged unmet need for pediatric cannabis toxicity treatment; Phase 1 SAD study of IV selonabant expected in H1 2025.","Closed $15M private placement with 22NW Fund, issuing 15.2M shares.","Amended loan with 22NW and JFL, reducing max to $3M and removing securitization."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178451,"accession_number":"0001493152-25-006036","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anebulo sets 2025 annual meeting for April 4; stockholder proposals due Feb 22","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for April 4, 2025; location to be in proxy materials.","Stockholder proposals for inclusion in proxy must be received by February 22, 2025.","Director nominations and other proposals not in proxy also due by February 22, 2025.","Universal proxy rule compliance deadline is February 22, 2025 (10 days after 8-K filing).","Meeting date more than 30 days after prior year's anniversary, resetting prior deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195121,"accession_number":"0001493152-24-051853","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","5.01","8.01","9.01"],"status":"ready","headline":"Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.","FDA acknowledged unmet need for pediatric cannabis toxicity and proposed close collaboration to efficiently advance IV selonabant program.","Plans to begin Phase 1 SAD study of IV selonabant in healthy adults in 1H 2025.","Will modify Loan & Security Agreement with 22NW and JFL Capital: reduce max loan to ~$3M, remove securitization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195120,"accession_number":"0001493152-24-045133","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.","Operating expenses of $2.4M, down from $2.5M year-over-year.","Cash $1.4M at Sept 30, 2024; access to $10M loan facility.","Awarded $1.9M NIDA grant to support IV selonabant development.","Plans to enroll first healthy volunteer in IV study in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195119,"accession_number":"0001493152-24-041362","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anebulo updates corporate presentation; no specific changes disclosed in filing extract","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated Corporate Presentation as Exhibit 99.1 under Item 7.01.","Presentation content is not included in the provided text; details of updates are unknown.","No forward-looking statements or material financial data were available for review.","Investors should request the full presentation from the company for substantive changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211398,"accession_number":"0001493152-24-038112","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.","Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.","Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.","Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.","Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211397,"accession_number":"0001493152-24-028629","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo awarded up to $1.9M NIDA grant for IV selonabant development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.","Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.","Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.","CEO notes grant validates progress and supports IV formulation clinical testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230024,"accession_number":"0001493152-24-024096","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo adopts new non-employee director equity compensation policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial grant of option to purchase 50,000 shares, vesting monthly over 3 years.","Annual grant of option to purchase 25,000 shares, vesting 1 year or next annual meeting.","All options expire 10 years from grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230023,"accession_number":"0001493152-24-019877","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).","Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.","Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.","DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.","Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248467,"accession_number":"0001493152-24-006087","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.","Cash $6.6M at Dec 31, 2023; secured $10M credit facility from existing investors.","Selonabant (ANEB-001) generic name adopted; IV formulation in development.","Targeting Phase 3 study start in H1 2024; new CEO Richie Cunningham and board member Bimal Shah."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265973,"accession_number":"0001493152-23-042292","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Anebulo stockholders approve increase in authorized shares and re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Jason M. Aryeh and Bimal Shah as Class III directors with ~23.1M votes for each.","Ratified EisnerAmper LLP as independent auditor for fiscal 2024 (23,302,065 for, 2,075 against).","Approved amendment to increase authorized common shares from 40M to 50M (23,263,127 for).","The authorized share amendment was filed with Delaware Secretary of State on Nov 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265972,"accession_number":"0001493152-23-041137","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.","Cash $8.5M as of Sep 30; secured credit facility of up to $10M from existing investors.","FDA Type B meeting: single ED study plus larger THC challenge may suffice for NDA for ANEB-001.","Richie Cunningham appointed CEO and Board member; Bimal Shah joined Board; Phase 3 targeted H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265971,"accession_number":"0001493152-23-036500","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anebulo terminates CEO Simon Allen, appoints Richie Cunningham as new CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Allen terminated without cause as CEO; resigned from board effective Oct 5, 2023.","Richie Cunningham appointed CEO and board member; previously CEO of Tyme Technologies and IXC Discovery.","Cunningham receives $450k base salary, time-vesting option for 600k shares (16 quarterly installments), and performance-based option for 140k shares.","Bimal Shah appointed to board and to Audit and Compensation Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283193,"accession_number":"0001493152-23-034696","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anebulo appoints part-time CFO Daniel George replacing Sandra Gardiner effective Sept 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel George appointed part-time CFO, principal financial and accounting officer; replaces Sandra A. Gardiner.","Compensation at $400/hour; typical schedule up to 10 hours per week, remote from Morgan Hill, CA.","Mr. George previously CFO of Lucira Health (2020-2022) and runs a consulting practice since Dec 2022.","Offer letter filed as Exhibit 10.1 includes standard at-will and arbitration provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283192,"accession_number":"0001493152-23-033196","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.","Cash and cash equivalents at June 30, 2023 were $11.2 million.","Positive FDA Type B meeting supports advancing ANEB-001 to registrational studies; Phase 3 targeting H1 2024.","Dosing completed in Part C open-label extension of Phase 2 study; data readout expected Q4 2023.","Operating expenses in FY2023 were $11.8M, up from $6.8M, driven by R&D and G&A increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283191,"accession_number":"0001493152-23-031568","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["1.02","5.02"],"status":"ready","headline":"Anebulo Pharmaceuticals' Acting CFO resigns as advisory agreement with Potrero terminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Potrero Hill Advisors terminated Master Services Agreement with Anebulo effective Sept 28, 2023.","Sandra Gardiner resigned as Acting CFO, principal financial and accounting officer, effective Sept 28.","Gardiner offered limited transition support to successor post-termination, subject to further discussion.","Company warns of risk to financing/accounting function if successor not found by termination date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302595,"accession_number":"0001493152-23-016291","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q3 FY2023 net loss of $2.8M ($0.11/share); cash $14.2M; positive Phase 2 data for ANEB-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.8M ($0.11 per share) vs $1.9M ($0.08) in Q3 FY2022.","Operating expenses $2.9M, up from $1.9M year-over-year.","Cash and cash equivalents $14.2M as of March 31, 2023.","Announced positive complete Phase 2 data for ANEB-001 in acute cannabinoid intoxication.","Type B meeting with FDA scheduled for July 2023 to discuss registrational path."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302594,"accession_number":"0001493152-23-011805","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo furnishes Part B final data charts for ANEB-001 Phase 2 trial, consistent with prior results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exhibit 99.1 contains graphical charts of Part B final data from Phase 2 trial of ANEB-001 for acute cannabinoid intoxication.","Data shown is consistent with results reported in the March 28, 2023 Form 8-K.","Trial was randomized, double-blind, placebo-controlled in healthy volunteers challenged with oral delta-9-THC.","No new clinical findings or updated guidance are provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322255,"accession_number":"0001193125-23-081417","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).","Pre-specified pooled analysis at 21/30 mg THC showed significance on all primary outcomes (p<0.02 for each).","ANEB-001 was well tolerated; no serious adverse events; mild to moderate THC symptoms observed before dosing.","High-fat meal blunted THC effects, but 10 mg ANEB-001 still significantly reduced VAS feeling high (p=0.003).","Company expects End of Phase 2A meeting with FDA by mid-2023 to discuss path forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322254,"accession_number":"0001493152-23-006974","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.","Gardiner replaces Rex Merchant; she will provide services through Master Services Agreement with Potrero Hill Advisors.","Gardiner previously served as CFO of Pulse Biosciences (Nasdaq: PLSE) and Cutera, Inc.","Master Services Agreement has five-year term, hourly rate compensation with annual 5% increase option, and 30-day termination notice.","No direct agreement between Company and Gardiner; all terms governed by the consulting arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322253,"accession_number":"0001493152-23-004202","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.","Cash and cash equivalents of $16.4M as of Dec 31, 2022.","Completed dosing Phase 2 trial for ANEB-001; preliminary data shows 10mg dose reduces key ACI symptoms.","Final Phase 2 data expected by end Q1 2023; End-of-Phase 2A meeting with FDA expected Q2 2023.","Continued development of parenteral formulation of ANEB-001."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322252,"accession_number":"0001493152-23-000900","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.","Delayed dosing of ANEB-001 (1 hour after THC) rapidly reversed pre-existing effects.","Full PK, PD, and safety data expected by end of 1Q2023; FDA End of Phase 2A meeting targeted H1 2023.","Cash of $16M as of Dec 31, 2022 provides runway into 2024.","No serious adverse events; 134 subjects enrolled in Parts A and B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340308,"accession_number":"0001493152-22-031235","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).","Cash $19.2M at Sept 30, 2022; cash burn $2.0M in quarter.","Positive interim data for ANEB-001 from Phase 2 Part B announced.","Closed $6.6M private placement financing in September 2022.","Appointed Nat Calloway, Ph.D. to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340307,"accession_number":"0001493152-22-029837","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anebulo shareholders elect three Class II directors, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Nat Calloway (15,985,642 for, 7,456 withheld), Areta Kupchyk (15,982,304 for, 10,794 withheld), Kenneth Lin (15,982,304 for, 10,794 withheld).","Ratification of EisnerAmper LLP as independent auditor for FY2023 approved: 15,992,762 for, 335 against, 1 abstention.","No broker non-votes on director elections; broker discretionary voting allowed on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340306,"accession_number":"0001493152-22-028331","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Anebulo Pharmaceuticals adopts amended bylaws to comply with universal proxy rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors adopted Amended and Restated Bylaws on October 11, 2022.","Updated advance notice procedures for stockholder proposals to require additional information.","Added classified Board provision consistent with existing certificate of incorporation.","Implemented supermajority stockholder vote requirement for any future bylaw amendments.","Removed President's authority to call special meetings of stockholders or the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357579,"accession_number":"0001493152-22-027158","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Anebulo raises $6.6M in private placement of common shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,264,650 units at $2.935 each for aggregate proceeds of ~$6.6 million; each unit consists of one share and one warrant.","Warrants exercisable at $4.215 per share, immediately exercisable, five-year term; beneficial ownership limitation applies.","22NW Fund, LP, an affiliate of director Aron English, purchased 1,703,577 units for ~$5.0 million.","Net proceeds to advance development of ANEB-001 (acute cannabinoid intoxication) and for general corporate purposes.","MTS Securities acted as placement agent; fee of 6% of gross proceeds (1% for 22NW participation) plus expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357578,"accession_number":"0001493152-22-026752","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.","Placebo group: 100% of subjects met VAS threshold for feeling high; only 1 subject per active dose group met threshold.","Safety: adverse events mild/transient except two moderate dizziness cases in Cohort 1 likely THC-attributable.","Company continuing Part B, enrolling third cohort; collaborating with FDA MIDD group on PK/PD model to optimize dosing for ACI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357577,"accession_number":"0001493152-22-025445","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q4 net loss $0.10/share; cash $14.5M; positive Phase 2 data for ANEB-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 fiscal 2022 net loss of $2.3M ($0.10 per share), vs $29.1M ($1.59) in prior year quarter.","Operating expenses Q4 $2.3M; fiscal year $6.8M; cash burn Q4 $2.0M; cash at June 30 $14.5M.","Positive Phase 2 Part A topline: ANEB-001 significantly reduced VAS feeling high (p<0.0001) and improved alertness (p<0.01).","Plan to initiate Part B evaluating lower doses by end of Q3 2022; IND submission for U.S. trials by end of 2022.","Inaugural R&D Day scheduled for September 26, 2022 in New York City; Part B data to be presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357576,"accession_number":"0001493152-22-018455","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.","Only 10% (50mg) and 30% (100mg) reported feeling high vs 75% placebo (p<0.001).","ANEB-001 well tolerated; all AEs mild/transient except one moderate nausea/vomiting in 50mg group.","Part B of study planned for Q3 2022; U.S. IND submission expected by end of 2022.","Conference call at 8:30am ET today to discuss topline results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376169,"accession_number":"0001493152-22-014942","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anebulo appoints Kenneth Cundy as CSO; $350K salary, options, milestone vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cundy appointed CSO effective May 20, 2022; base salary $350,000, annual bonus up to 30%.","Receives option for 233,446 shares vesting quarterly over 4 years.","Additional option for 116,273 shares vests upon FDA approval of lead candidate ANEB-001.","Severance: 9 months' base salary plus COBRA for up to 12 months if terminated without cause.","Cundy previously CSO at CohBar and XenoPort; coinventor of tenofovir and Nanocrystal technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376168,"accession_number":"0001493152-22-012786","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.","Operating expenses rose to $1.9M from $0.6M in prior year period.","Cash and cash equivalents totaled $16.5M as of March 31, 2022.","Completed enrollment of 60 subjects in Part A of Phase 2 trial for ANEB-001; top-line data expected by June 30, 2022.","Company scheduled to present at four investor conferences and a cannabinoid symposium in May-June 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376167,"accession_number":"0001493152-22-008679","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo doses >50% of subjects in Phase 2 trial for acute cannabinoid intoxication; expects IND by end of 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed more than half of the 60 planned subjects in Part A of Phase 2 trial for ANEB-001 at CHDR in Netherlands.","Top-line data for Part A expected by end of H1 2022.","Plan to include Part A data in IND submission to FDA; expects to file IND before end of 2022.","CEO Simon Allen states robust enrollment enables smoother bridge to U.S. trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394524,"accession_number":"0001493152-22-003881","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.","Cash and cash equivalents $18.0M as of Dec 31, 2021; cash burn $1.2M in Q2.","Initiated Phase 2 proof-of-concept study for ANEB-001 for acute cannabinoid intoxication; topline results expected H1 2022.","Simon Allen appointed CEO effective Feb 1, 2022; previously CBO at Ambrx.","FDA pre-IND meeting provided guidance; U.S. patent issued for ANEB-001 (expires 2040)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394523,"accession_number":"0001493152-22-000406","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anebulo Pharmaceuticals names Simon Allen CEO effective Feb 1, 2022; Dr. Schneeberger resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Allen appointed CEO and director, effective Feb 1, 2022; succeeds Daniel Schneeberger.","Dr. Schneeberger's resignation not due to any disagreement with company operations or policies.","Allen receives $450k base salary; stock options for 625k shares at $6.21 vesting quarterly over 4 years.","Allen eligible for $1.5M cash bonus if company sold for ≥$500M with Board approval.","Severance of 9 months base salary plus COBRA reimbursement for 12 months if terminated without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394522,"accession_number":"0001493152-22-000100","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anebulo doses first patient in Phase 2 study of ANEB-001 for acute cannabinoid intoxication; expects topline in 1H 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2 proof-of-concept study evaluating ANEB-001 for acute cannabinoid intoxication.","Part A will enroll 60 patients randomized 1:1:1 to 50mg, 100mg ANEB-001 or placebo, all receiving 10.5mg THC challenge.","Initial topline results from Part A expected in first half of 2022.","FDA pre-IND meeting provided guidance; Anebulo expects to submit IND in Q1 2022.","FDA accepted a THC challenge model for efficacy; company plans MIDD paired-meeting request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413140,"accession_number":"0001493152-21-028944","cik":1815974,"company_name":"Anebulo Pharmaceuticals, Inc.","ticker":"ANEB","form_type":"8-K","filed_at":"2021-11-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anebulo annual meeting: directors elected, stock plan amended with 2M additional shares, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected three Class I directors: Joseph Lawler, Daniel Schneebeger, Aron English.","Amendment to 2020 Stock Incentive Plan approved, increasing authorized shares by 2,000,000 to 3,650,000 (13.55M for, 69K against).","Appointment of EisnerAmper LLP as independent auditor for FY2022 ratified (14,080,531 for, 0 against, 737 abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":19168823.30434782,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-16T23:59:59+00:00|413140"}